The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, Tuba/0000-0003-1814-5972
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridAKPINAR, SEVAL/0000-0002-6961-8971
dc.authoridÇelik, Serhat/0000-0002-1052-9800
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridAfacan Öztürk, Hacer Berna/0000-0001-9386-7604
dc.authoridSERIN, Istemi/0000-0003-1855-774X
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidArslan Davulcu, Eren/JAX-2610-2023
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidAKPINAR, SEVAL/HKD-9650-2023
dc.authorwosidÇelik, Serhat/IWU-4452-2023
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidAkgun Cagliyan, Gulsum/AAA-5330-2022
dc.contributor.authorAkpinar, Seval
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorCelik, Serhat
dc.contributor.authorEkinci, Omer
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorDavulcu, Eren Arslan
dc.date.accessioned2024-08-04T20:50:44Z
dc.date.available2024-08-04T20:50:44Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clml.2021.09.010
dc.identifier.endpage173en_US
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue3en_US
dc.identifier.pmid34629286en_US
dc.identifier.scopus2-s2.0-85116827763en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage169en_US
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.09.010
dc.identifier.urihttps://hdl.handle.net/11616/100257
dc.identifier.volume22en_US
dc.identifier.wosWOS:000760119700011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic lymphocytic leukemiaen_US
dc.subjectBruton tyrosine kinaseen_US
dc.subjectIbrutiniben_US
dc.subjectRelapsed/refractoryen_US
dc.subjectp53 mutationen_US
dc.titleThe Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLLen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu